Allogeneic stem cell transplant for myelofibrosis patients over age 60: likely impact of the JAK2 inhibitors - Wikidata - awgldk - TriplyDB

Allogeneic stem cell transplant for myelofibrosis patients over age 60: likely impact of the JAK2 inhibitors

Allogeneic stem cell transplant for myelofibrosis patients over age 60: likely impact of the JAK2 inhibitors

http://www.wikidata.org/entity/Q26863610

about

The new landscape of therapy for myelofibrosis.Between a rux and a hard place: evaluating salvage treatment and outcomes in myelofibrosis after ruxolitinib discontinuation.

P2860

Q38150261-9D87F350-3A9F-4152-A0FE-0FF0FBB2DC41 Q49490860-089EE206-3B01-4FD3-82DC-C9A140AC975A

P2860

Allogeneic stem cell transplant for myelofibrosis patients over age 60: likely impact of the JAK2 inhibitors

http://www.wikidata.org/entity/Q26863610

description

2012 nî lūn-bûn

@nan

2012 թուականի Մայիսին հրատարակուած գիտական յօդուած

@hyw

2012 թվականի մայիսին հրատարակված գիտական հոդված

@hy

2012年の論文

@ja

2012年学术文章

@wuu

2012年学术文章

@zh-cn

2012年学术文章

@zh-hans

2012年学术文章

@zh-my

2012年学术文章

@zh-sg

2012年學術文章

@yue

name

Allogeneic stem cell transplan ...... impact of the JAK2 inhibitors

@ast

Allogeneic stem cell transplan ...... impact of the JAK2 inhibitors

@en

Allogeneic stem cell transplan ...... impact of the JAK2 inhibitors

@nl

type

label

Allogeneic stem cell transplan ...... impact of the JAK2 inhibitors

@ast

Allogeneic stem cell transplan ...... impact of the JAK2 inhibitors

@en

Allogeneic stem cell transplan ...... impact of the JAK2 inhibitors

@nl

prefLabel

Allogeneic stem cell transplan ...... impact of the JAK2 inhibitors

@ast

Allogeneic stem cell transplan ...... impact of the JAK2 inhibitors

@en

Allogeneic stem cell transplan ...... impact of the JAK2 inhibitors

@nl

P1433

Q26863610-7240D6C4-6756-4EF0-B61C-6DFB4D5DE357

P1476

Q26863610-1833599B-30DE-42D2-BCA4-86BE5C72E1E6

P2093

Q26863610-2EB73D1A-3B26-44F8-8E1E-459B4AAD6FD6

Q26863610-CBD421D4-206F-4642-A9FB-BBDE27C47451

Q26863610-CE50E2C0-7613-46D8-9E49-C13C2FDB92A9

P2860

Q26863610-01084C6F-7426-4083-A9ED-F106487071F3

Q26863610-14A8373D-9355-4A88-9C75-F750B2E1B372

Q26863610-16EB84B1-3D10-4B3B-A66B-4B5C458FAB1F

Q26863610-1C218243-3A64-427E-B837-6647F13D243D

Q26863610-3FB80169-490E-40D3-BACC-DC56B7BA4B34

Q26863610-408FF40D-6AF2-4A8F-AE71-DAA35854CFC5

Q26863610-421A8B6E-0CAD-4512-BFC7-79DF439F35CD

Q26863610-4AE5729C-14E2-4F6A-A05B-3F21D7522605

Q26863610-513B30AE-511C-479B-BC87-2A7EED37581C

Q26863610-5B0126F5-680D-4E46-857F-30AE72D33C90

P2888

Q26863610-9CAA9995-C21B-4781-8BA5-20729B126EF5

P304

Q26863610-066025B5-B798-412B-8220-F64FED2E8C81

P31

Q26863610-15E4A07E-E2E8-45C7-B2BD-A54877717F56

Q26863610-5a9a540a-6a3b-42c2-847f-d5c749965644

P356

Q26863610-D7D7721C-F1F4-439C-86A4-A82A7173118D

P407

Q26863610-C4267982-BDD8-40B1-8456-80936CF8F7B1

P433

Q26863610-87DBCEE4-F2F2-4A53-AAE3-523DA1FB2E5B

P478

Q26863610-8EFB50D9-6FEC-4D3F-8508-4491DA42A1C6

P577

Q26863610-4A753E5A-4099-4E73-9710-B9E861B2048E

P6179

Q26863610-DD2288DE-9013-4C5A-9947-6255D01D3B48

P698

Q26863610-BED13565-9D99-47EF-BAAB-E27BB032E448

P932

Q26863610-6D83D2C8-E4C9-42DF-B81B-A646D28BBFAF

P356

P1433

Leukemia supplements

P1476

Allogeneic stem cell transplan ...... impact of the JAK2 inhibitors

@en

P2093

J Leis

http://www.w3.org/2001/XMLSchema#string

R A Mesa

http://www.w3.org/2001/XMLSchema#string

V Fauble

http://www.w3.org/2001/XMLSchema#string

P2860

Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study

Splenectomy in myelofibrosis with myeloid metaplasia: a single-institution experience with 223 patients.

A phase 2 trial of combination low-dose thalidomide and prednisone for the treatment of myelofibrosis with myeloid metaplasia.

Lenalidomide therapy in myelofibrosis with myeloid metaplasia.

Palliative goals, patient selection, and perioperative platelet management: outcomes and lessons from 3 decades of splenectomy for myelofibrosis with myeloid metaplasia at the Mayo Clinic.

Safety and efficacy of INCB018424, a JAK1 and JAK2 inhibitor, in myelofibrosis.

A phase-2 trial of low-dose pomalidomide in myelofibrosis.

DIPSS plus: a refined Dynamic International Prognostic Scoring System for primary myelofibrosis that incorporates prognostic information from karyotype, platelet count, and transfusion status.

Safety and efficacy of TG101348, a selective JAK2 inhibitor, in myelofibrosis.

Circulating interleukin (IL)-8, IL-2R, IL-12, and IL-15 levels are independently prognostic in primary myelofibrosis: a comprehensive cytokine profiling study.

P2888

P304

S2-7

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/LEUSUP.2012.2

http://www.w3.org/2001/XMLSchema#string

P407

P433

Suppl 1

http://www.w3.org/2001/XMLSchema#string

P478

1

http://www.w3.org/2001/XMLSchema#string

P577

2012-05-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P6179

1024760573

http://www.w3.org/2001/XMLSchema#string

P698

27175229

http://www.w3.org/2001/XMLSchema#string

P932

4851182

http://www.w3.org/2001/XMLSchema#string